Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy

 
• By Kevin Grogan

Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.

Wallet
Novartis has opened its wallet again for another bolt-on • Source: Shutterstock

More from Deals

More from Business